Vitro Diagnostics, Inc.

48 articles about Vitro Diagnostics, Inc.

• Vitro Biopharma Announces Changes in SEC Registration

  10/13/2020

  Vitro Diagnostics, Inc. announced the revocation of its SEC registration for Vitro Diagnostics, Inc while also announcing its plans for re-registration with the SEC.

• Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations

  10/1/2020

  Vitro Diagnostics, Inc., dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2020, financial results of operations.

• Vitro Biopharma Announces MaloneBailey L.L.P. as its new Auditors

  7/20/2020

  Vitro Diagnostics, Inc.. (OTC PINK:VODG), dba Vitro Biopharma, announced that it has engaged MaloneBailey L.L.P. (Certified Public Accounting Firm www.malonebailey.com ) as its new auditors that will be auditing the company's consolidated balance sheets as of October 31, 2019 and October 31, 2020

• Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells(R)

  7/14/2020

  Vitro Diagnostics, Inc., dba Vitro Biopharma, jointly with GIOSTAR - a San Diego, California-based institution headed by Dr. Anand Srivastava, a pioneer in stem cell science - announced the results of treatment of a critically ill COVID-19 patient with its lead clinical product AlloRx Stem Cells®.

• Vitro Biopharma Announces Dr. Jack Zamora M.D. as it's Chief Medical Advisor

  7/13/2020

  Vitro Diagnostics, Inc., dba Vitro Biopharma, announced that Dr. Jack Zamora M.D. has joined its executive team as its Chief Medical Advisor.

• Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

  6/4/2020

  Vitro Diagnostics, Inc., dba Vitro entered into an exclusive Memorandum of Understanding with Global Institute of Stem Cell Therapy and Research, Inc. a leading stem cell research institute based in San Diego, California to jointly partner together for a COVID-19 Investigational New Drug to the FDA using Vitro Biopharma's umbilical cord mesenchymal stem cell product AlloRx Stem Cells™ in a clinical trial to treat Covid-19 patients.

• Vitro Biopharma Launches Products for Drug Development & Advancement of Joint Regeneration Technology

  10/9/2012

• Vitro Diagnostics Develops Novel Stem Cell Technology for Use in Treatment of Hearing Loss

  10/4/2011

• Vitro Diagnostics Launches New Stem Cell Products for Clinical Use & Presents Webinar with HemoGenix Inc.

  7/20/2011

• Vitro Diagnostics Appoints Accomplished Finance Executive to Its Advisory Board

  6/2/2011

• Vitro Diagnostics Out-licenses Patents, Products & Technology for Treatment of Infertility

  3/31/2011

• Vitro Diagnostics Release: New Results Reveal Extensive Competitive Advantages of VitroGrow(TM) Stem Cell Culture Media

  12/15/2010

• Vitro Diagnostics Expands HemoGenix Inc. Alliance to Include Cell-based Testing for Liver Toxicity

  10/19/2010

• Vitro Diagnostics Enters Contract to Develop Stem Cell-Derived Food

  7/27/2010

• Vitro Diagnostics and HemoGenix Inc. Launch New Products at an International Stem Cell Meeting

  6/15/2010

• Vitro Diagnostics Announces Open Letter to Its Shareholders: Current Results and Future Prospects

  5/18/2010

• Vitro Diagnostics Forms Strategic Alliance With a Leading Stem Cell Company HemoGenix Inc.

  4/28/2010

• Recent Advances Lead to a Breakthrough Method for Expanded Medical Use of Adult Stem Cells

  3/31/2010

• Vitro Diagnostics Appoints Prominent Denver Investment Banker to Its Board of Directors

  2/23/2010

• Vitro Diagnostics Co-sponsors Keystone Stem Cell Symposium

  2/16/2010